Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Durect
Biotech
Durect fails alcohol-associated hepatitis trial, plans phase 3
The biotech hailed “remarkable” results but failed to persuade investors to look past the failure of the primary endpoint, causing its stock to sink.
Nick Paul Taylor
Nov 8, 2023 7:57am
Catalent shakes up leadership, taps new CEO—Chutes & Ladders
Jul 8, 2022 9:30am
Durect's painkiller gets evenly split decision from expert panel
Jan 17, 2020 8:30am
Durect shares rocked by midstage psoriasis flop
Jan 3, 2020 8:00am
AASLD: Durect's alcoholic hepatitis med shows early promise
Nov 12, 2019 8:45am
Novartis, Durect amend $293M painkiller deal after phase 3 loss
May 9, 2018 10:48am
